FATE - Fate Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-109M

Cash

377.9M

Avg Qtr Burn

-46.95M

Short % of Float

16.46%

Insider Ownership

1.45%

Institutional Own.

-

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
FT576 (iNK hnCD16) + daratumumab Details Cancer, Multiple myeloma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT819 (CAR-19, TCR-KO) Details Solid tumor/s, Cancer, B-cell lymphoma, Chronic lymphocytic leukemia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT522 (CAR NK Cell Program) Details Cancer, B-cell lymphoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT516 (NK cells - engineered CD16 FcR) Details Solid tumor/s, B-cell lymphoma, Diffuse large B cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT596 (CAR19, hnCD16, IL-15RF) + rituximab Details B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT538 (hnCD16 + IL-15RF + CD38KO) Details Multiple myeloma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT500 (PD1/PD-L1) Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT596 (CAR19, hnCD16, IL-15RF) + R-CHOP Details B-cell lymphoma, B-cell malignancies, Chronic lymphocytic leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ProTmune (CD34+) Details Acute graft-versus host disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
FT516 (NK cells - engineered CD16 FcR) + rituximab Details Solid tumor/s, B-cell lymphoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.